Abrysvo

BIOLOGICAL8 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Pfizer, PENTA Foundation, Centre Hospitalier Annecy Genevois, Wits Health Consortium

Conditions

Acute Respiratory Illness (ARI)Lower Respiratory Tract DiseaseRSV ImmunizationRespiratory Respiratory Syncytial Virus InfectionRespiratory Syncytial VirusRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus InfectionRespiratory Syncytial Virus Infections

Phase 3

RecruitingPACTR202504593185463

Wits Health ConsortiumRespiratory Respiratory Syncytial Virus Infection

Start: 2025-05-01Target: 13000Updated: 2026-08-03

Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.

Not yet recruitingNCT07041190

PENTA FoundationRSV Immunization

Start: 2025-09-30End: 2028-12-31Target: 1500Updated: 2025-06-27

Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination

RecruitingNCT07232706

Centre Hospitalier Annecy GenevoisRSV Immunization

Start: 2026-05-06End: 2029-05-05Target: 1000Updated: 2026-05-27

Phase 4

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

CompletedNCT06551506

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infection

Start: 2024-09-19End: 2026-05-05Updated: 2026-05-11

Unknown Phase

Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy

Active, not recruitingNCT06647654

PfizerRespiratory Syncytial Virus, Respiratory Tract Diseases

Start: 2024-08-26End: 2026-10-15Updated: 2026-05-15

STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)

Active, not recruitingNCT07122661

PfizerAcute Respiratory Illness (ARI), Lower Respiratory Tract Disease, Respiratory Syncytial Virus +2

Start: 2025-08-11End: 2027-04-30Target: 1Updated: 2025-11-19

Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset

Not yet recruitingNCT07235397

PfizerRespiratory Syncytial Virus Infections

Start: 2026-07-30End: 2026-11-13Target: 1Updated: 2026-07-01

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Active, not recruitingNCT07249320

PfizerRespiratory Syncytial Virus (RSV)

Start: 2025-12-01End: 2027-09-30Updated: 2026-06-10